Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Ixekizumab - Eli Lilly

Drug Profile

Ixekizumab - Eli Lilly

Alternative Names: LY-2439821; Taltz

Latest Information Update: 19 Dec 2018

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Eli Lilly
  • Developer Eli Lilly; Oregon Health & Science University
  • Class Antibodies; Antipsoriatics; Antirheumatics; Monoclonal antibodies; Skin disorder therapies
  • Mechanism of Action IL17A protein inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Plaque psoriasis; Psoriatic arthritis
  • Registered Erythrodermic psoriasis; Pustular psoriasis
  • Phase III Ankylosing spondylitis; Spondylarthritis
  • Phase II Bullous pemphigoid; Pityriasis rubra pilaris; Pyoderma gangrenosum; Rheumatoid arthritis

Most Recent Events

  • 06 Nov 2018 Eli Lilly completes the phase III SPIRIT P3 trial for Psoriatic arthritis (Treatment-experienced) in USA, Argentina, Bulgaria, the Czech Republic, Estonia, Spain, the UK, Mexico, Russia, Slovakia, Ukraine, South Africa and Poland (NCT02584855)
  • 22 Oct 2018 Safety and adverse events data from the COAST-V and COAST-W phase III trial in Ankylosing spondylitis presented at the 82nd American College of Rheumatology and the 52nd Association of Rheumatology Health Professionals Annual Scientific Meeting(ACR/RHP)
  • 19 Oct 2018 Updated efficacy and safety data from the phase III COAST-W trial in Ankylosing spondylitis presented at the 82nd American College of Rheumatology and the 52nd Association of Rheumatology Health Professionals Annual Scientific Meeting (ACR/ARHP-2018)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top